Research ArticleCardiovascular and Metabolic Risk
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
John B. Buse, Satish K. Garg, Julio Rosenstock, Timothy S. Bailey, Phillip Banks, Bruce W. Bode, Thomas Danne, Jake A. Kushner, Wendy S. Lane, Pablo Lapuerta, Darren K. McGuire, Anne L. Peters, John Reed, Sangeeta Sawhney, Paul Strumph
DOI: 10.2337/dc18-0343 Published 1 September 2018
John B. Buse
1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
Satish K. Garg
2Departments of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO
Julio Rosenstock
3Dallas Diabetes Research Center at Medical City, Dallas, TX
Timothy S. Bailey
4AMCR Institute, Escondido, CA
Phillip Banks
5Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Bruce W. Bode
6Atlanta Diabetes Associates, Emory University School of Medicine, Atlanta, GA
Thomas Danne
7Department of Diabetes, Endocrinology, and Clinical Research, Children’s and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany
Jake A. Kushner
8McNair Medical Institute and Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX
Wendy S. Lane
9Mountain Diabetes and Endocrine Center, Asheville, NC
Pablo Lapuerta
5Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Darren K. McGuire
10Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Anne L. Peters
11Keck School of Medicine of the University of Southern California, Los Angeles, CA
John Reed
12Endocrine Research Solutions, Inc., Roswell, GA
Sangeeta Sawhney
5Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Paul Strumph
5Lexicon Pharmaceuticals, Inc., The Woodlands, TX